Anne Li August 26th, 2017 email@example.com
Determining which cancer patients are likely to be resistant to initial treatment is a major research effort of oncologists and laboratory scientists. Now, ascertaining who might fall into that category may become a little easier for physicians taking care of people with BRCA1/2 mutations. Researchers in the Perelman School of Medicine at the University of Pennsylvania found a relationship between the genetics of tumors with germline BRCA1/2mutations and whether the tumor retains the normal copy of the BRCA1/2 gene.
See original article at: https://www.sciencedaily.com/releases/2017/08/170822111106.htm